PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF THE POTENTIAL-DRUG INTERACTION BETWEEN VENLAFAXINE AND DIAZEPAM

被引:36
作者
TROY, SM
LUCKI, I
PEIRGIES, AA
PARKER, VD
KLOCKOWSKI, PM
CHIANG, ST
机构
[1] UNIV PENN,DEPT PSYCHIAT,PHILADELPHIA,PA 19104
[2] UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104
[3] ONEIDA RES SERV INC,WHITESBORO,NY
关键词
D O I
10.1002/j.1552-4604.1995.tb04082.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To assess possible pharmacokinetic and pharmacodynamic interactions between the antidepressant venlafaxine and diazepam, a randomized, two-period, crossover study was conducted in 18 men. Multiple-dose venlafaxine (50 mg every 8 hours) or placebo (double-blind) was given for 10 days; on day 4 a single placebo dose (same appearance as diazepam capsule, single-blind) was given; and on day 5 a single dose of diazepam (10 mg) was given. Pharmacokinetic data indicated that diazepam had no significant effect on venlafaxine or O-desmethylvenlafaxine disposition. Diazepam pharmacokinetics were minimally changed in the presence of venlafaxine, Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (V-z/f) increased (0.85 +/- 0.28 Versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng . h/mL; P = .02), Venlafaxine did not alter desmethyldiazepam pharmacokinetics, Pharmacodynamic data showed a statistically significant diazepam-venlafaxine interaction for only one of the eight psychometric tests given. Critical flicker fusion slightly decreased (P = .01) between placebo-diazepam (37.85 +/- 3.28 Hz) and venlafaxine-diazepam (37.09 +/- 4.13 Hz) treatments, The observed pharmacokinetic and pharmacodynamic interactions between diazepam and venlafaxine were small and probably clinically insignificant.
引用
收藏
页码:410 / 419
页数:10
相关论文
共 50 条
  • [1] Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol
    Troy, SM
    Turner, MB
    Unruh, M
    Parker, VD
    Chiang, ST
    JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (11) : 1073 - 1081
  • [2] EVALUATION OF A POTENTIAL-DRUG INTERACTION BETWEEN SUCRALFATE AND ASPIRIN
    LAU, A
    CHANG, CW
    SCHLESINGER, P
    GASTROENTEROLOGY, 1985, 88 (05) : 1465 - 1465
  • [3] EVALUATION OF A POTENTIAL-DRUG INTERACTION BETWEEN SUCRALFATE AND ASPIRIN
    LAU, A
    CHANG, CW
    SCHLESINGER, P
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (06): : 457 - 457
  • [4] EVALUATION OF A POTENTIAL-DRUG INTERACTION BETWEEN SUCRALFATE AND ASPIRIN
    LAU, AH
    CHANG, CW
    SCHLESINGER, PK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) : 151 - 155
  • [5] EVALUATION OF A POTENTIAL-DRUG INTERACTION BETWEEN LEVONORDEFRIN AND CYCLOBENZAPRINE
    NGUYEN, AM
    GAGE, TW
    DORRIS, RL
    JOURNAL OF DENTAL RESEARCH, 1990, 69 : 331 - 331
  • [6] Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling Approach
    Ji, Beihong
    Xue, Ying
    Xu, Yuanyuan
    Liu, Shuhan
    Gough, Albert H.
    Xie, Xiang-Qun
    Wang, Junmei
    ACS CHEMICAL NEUROSCIENCE, 2021, 12 (10): : 1777 - 1790
  • [7] A POTENTIAL-DRUG INTERACTION BETWEEN FLUOXETINE AND VALPROIC ACID
    SOVNER, R
    DAVIS, JM
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1991, 11 (06) : 389 - 389
  • [8] PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION STUDY OF DIAZEPAM AND METOPROLOL
    KLOTZ, U
    REIMANN, IW
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (02) : 223 - 226
  • [9] Pharmacokinetic and pharmacodynamic drug interaction between flibanserin and fluconazole
    Lagishetty, Chakradhar V.
    Samant, Tanay S.
    Ge, Li
    Trame, Mirjam N.
    Natarajan, Karthi
    Yuan, James
    Torrente, Josephine M.
    Lesko, Lawrence J.
    Schmidt, Stephan
    DRUG METABOLISM REVIEWS, 2016, 48 : 77 - 77
  • [10] Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers
    Fleishaker, JC
    Herman, BD
    Pearson, LK
    Ionita, A
    Mucci, M
    CLINICAL DRUG INVESTIGATION, 1999, 18 (02) : 141 - 150